SG11201705986QA - Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders - Google Patents
Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disordersInfo
- Publication number
- SG11201705986QA SG11201705986QA SG11201705986QA SG11201705986QA SG11201705986QA SG 11201705986Q A SG11201705986Q A SG 11201705986QA SG 11201705986Q A SG11201705986Q A SG 11201705986QA SG 11201705986Q A SG11201705986Q A SG 11201705986QA SG 11201705986Q A SG11201705986Q A SG 11201705986QA
- Authority
- SG
- Singapore
- Prior art keywords
- alzheimer
- disease
- delivery systems
- antibody molecules
- related disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT10818215 | 2015-01-29 | ||
| PT10818115 | 2015-01-29 | ||
| PCT/IB2016/050467 WO2016120843A1 (en) | 2015-01-29 | 2016-01-29 | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705986QA true SG11201705986QA (en) | 2017-08-30 |
Family
ID=55409873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705986QA SG11201705986QA (en) | 2015-01-29 | 2016-01-29 | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10654917B2 (en) |
| EP (2) | EP4183795A1 (en) |
| JP (1) | JP6986967B2 (en) |
| CN (1) | CN107531781B (en) |
| AU (1) | AU2016210835B2 (en) |
| CA (1) | CA2975059C (en) |
| SG (1) | SG11201705986QA (en) |
| WO (1) | WO2016120843A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042853A1 (en) * | 2016-11-07 | 2018-05-11 | Crossbeta Biosciences B.V. | Novel amyloid beta oligomer specific binding molecule |
| EA202191179A1 (en) * | 2018-10-29 | 2021-09-09 | Байоджен Ма Инк. | HUMANIZED AND STABILIZED FC5 OPTIONS TO IMPROVE TRANSPORT THROUGH THE HEMATOENCEPHALIC BARRIER |
| US20200230218A1 (en) * | 2019-01-18 | 2020-07-23 | L & J Bio Co., Ltd. | Method of treating central nervous system disease |
| TW202300517A (en) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | Anti-amyloid beta antibodies and uses thereof |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| WO2022270396A1 (en) * | 2021-06-21 | 2022-12-29 | 株式会社Epsilon Molecular Engineering | Double-screening method |
| WO2023281445A1 (en) * | 2021-07-07 | 2023-01-12 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. | Highly specific rabbit single -domain antibodies for drug delivery in immunotherapy applications |
| CN116212049B (en) * | 2022-12-19 | 2023-11-24 | 江南大学 | Application of chiral nanomaterial based on microglial inflammatory aging regulation in preparation of medicine for treating Alzheimer disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU694745B2 (en) | 1993-09-10 | 1998-07-30 | Trustees Of Columbia University In The City Of New York, The | Uses of green fluorescent protein |
| US6311415B1 (en) | 1998-09-14 | 2001-11-06 | Lind Shoe Company | Bowling shoe with replaceable tip |
| US6962793B2 (en) * | 2000-10-27 | 2005-11-08 | Mount Sinai Hospital | Methods for detecting Alzheimers disease |
| DE60326153D1 (en) * | 2002-07-30 | 2009-03-26 | David Gladstone Inst | PROCESS FOR THE DIAGNOSIS OF MORBUS ALZHEIMER |
| JP2006508072A (en) * | 2002-10-01 | 2006-03-09 | ノースウエスタン ユニバーシティ | Amyloid beta-derived diffusible ligands (ADDLs), ADDL substitutes, ADDL-binding molecules, and uses thereof |
| US7763249B2 (en) * | 2004-04-27 | 2010-07-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid β peptide antibody and fragment of said antibody |
| CN101076543A (en) * | 2004-10-13 | 2007-11-21 | 阿布林克斯公司 | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
| KR20070084170A (en) | 2004-10-13 | 2007-08-24 | 아블린쓰 엔.브이. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
| US8263558B2 (en) * | 2005-11-30 | 2012-09-11 | Abbott Laboratories | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins |
| WO2008136694A1 (en) | 2007-05-04 | 2008-11-13 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Engineered rabbit antibody variable domains and uses thereof |
| JP5570998B2 (en) * | 2007-12-31 | 2014-08-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Antibody to TNFα |
| WO2010119704A1 (en) * | 2009-04-17 | 2010-10-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| EP2462161B1 (en) * | 2009-08-06 | 2017-03-08 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| EP2497782A1 (en) * | 2011-03-08 | 2012-09-12 | Alzinova AB | Anti oligomer antibodies and uses thereof |
| IN2014CN00414A (en) | 2011-06-23 | 2015-04-03 | Ablynx Nv | |
| SG11201400881SA (en) | 2011-09-23 | 2014-04-28 | Technophage Investigação E Desenvolvimento Em Biotecnologia Sa | Modified albumin-binding domains and uses thereof to improve pharmacokinetics |
| DK2802606T3 (en) | 2012-01-10 | 2018-06-25 | Biogen Ma Inc | INCREASE TRANSPORT OF THERAPEUTIC MOLECULES OVER THE BLOOD-BRAIN BARRIER |
| US9617332B2 (en) * | 2012-05-10 | 2017-04-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Conformational-specific antibodies against A[β] oligomers |
| WO2014060444A1 (en) * | 2012-10-15 | 2014-04-24 | Medimmune Limited | Antibodies to amyloid beta |
-
2016
- 2016-01-29 CA CA2975059A patent/CA2975059C/en active Active
- 2016-01-29 SG SG11201705986QA patent/SG11201705986QA/en unknown
- 2016-01-29 CN CN201680014071.4A patent/CN107531781B/en active Active
- 2016-01-29 EP EP22198181.4A patent/EP4183795A1/en active Pending
- 2016-01-29 AU AU2016210835A patent/AU2016210835B2/en active Active
- 2016-01-29 JP JP2017538943A patent/JP6986967B2/en active Active
- 2016-01-29 WO PCT/IB2016/050467 patent/WO2016120843A1/en active Application Filing
- 2016-01-29 US US15/545,399 patent/US10654917B2/en active Active
- 2016-01-29 EP EP16705995.5A patent/EP3250595A1/en active Pending
-
2020
- 2020-04-30 US US16/863,184 patent/US20210355200A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4183795A1 (en) | 2023-05-24 |
| US20210355200A1 (en) | 2021-11-18 |
| CA2975059A1 (en) | 2016-08-04 |
| US20180009883A1 (en) | 2018-01-11 |
| CA2975059C (en) | 2023-02-21 |
| CN107531781A (en) | 2018-01-02 |
| US10654917B2 (en) | 2020-05-19 |
| AU2016210835A1 (en) | 2017-08-10 |
| AU2016210835B2 (en) | 2021-01-21 |
| JP2018513670A (en) | 2018-05-31 |
| JP6986967B2 (en) | 2021-12-22 |
| AU2016210835A8 (en) | 2017-08-17 |
| CN107531781B (en) | 2021-12-07 |
| WO2016120843A1 (en) | 2016-08-04 |
| EP3250595A1 (en) | 2017-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201705986QA (en) | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders | |
| IL284250A (en) | Humanized tau antibodies in alzheimer's disease | |
| IL264144A (en) | Antibody for anti-claudin 18a2 and use thereof | |
| SG11202003320SA (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| PL3274321T3 (en) | Cannabidiol isolate from industrial-hemp and use thereof in pharmaceutical and/or cosmetic preparations | |
| HUE054201T2 (en) | Pd-1-cd28 fusion proteins and their use in medicine | |
| AU2016255474B2 (en) | Application of PI4KIIIα protein and related membrane protein complex in treating Alzheimer's disease | |
| HK1215540A1 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases 1 2 | |
| GB201512596D0 (en) | Biomolecules involved in Alzheimer's disease | |
| EP3377118A4 (en) | Methods for treating alzheimer's disease and related disorders | |
| PT3302454T (en) | Compositions for use in treating parkinson's disease and related disorders | |
| ZA201804079B (en) | Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease, or in the diagnosis of parkinson's disease | |
| PL3606546T3 (en) | Genetic construct for use in the treatment of neurodegenerative disorder or stroke | |
| HK1256814A1 (en) | Colloidal particles for use in medicine | |
| EP3747454C0 (en) | Amyloid-beta binding peptides and these peptides for use in the therapy and diagnosis of alzheimer's dementia | |
| IL251949A0 (en) | Small organic molecules for use in the treatment neuroinflammatory disorders | |
| EP3162377A4 (en) | Use of -asarone in preparing drugs for preventing and treating alzheimer's disease | |
| IL255229A (en) | Anionic nanoparticles for use in the delivery of anionic small molecule drugs | |
| HUE042456T2 (en) | Pharmaceutical solution comprising dopamine for use in treating parkinson's disease | |
| EP3110453A4 (en) | Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions | |
| EP3852772C0 (en) | Pharmaceutical product for use in treating alzheimer's disease | |
| GB201610205D0 (en) | Therapies for parkinson's disease | |
| HK1198937A1 (en) | Date extract based on two types of dates and the application of such extract in neurodegenerative disease and depression |